 James Liu
Concepts (285)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Estrogens | 9 | 2020 | 367 | 2.450 |
Why?
| | Postmenopause | 8 | 2021 | 392 | 1.570 |
Why?
| | Leiomyoma | 3 | 2021 | 61 | 1.310 |
Why?
| | Norpregnadienes | 2 | 2021 | 3 | 1.260 |
Why?
| | Estrogen Replacement Therapy | 8 | 2020 | 143 | 1.220 |
Why?
| | Estradiol | 6 | 2021 | 515 | 1.210 |
Why?
| | Pituitary Neoplasms | 4 | 2024 | 190 | 1.120 |
Why?
| | Vaginal Creams, Foams, and Jellies | 2 | 2018 | 4 | 1.080 |
Why?
| | Dyspareunia | 2 | 2018 | 8 | 1.080 |
Why?
| | Vulva | 2 | 2018 | 24 | 1.070 |
Why?
| | Adenoma | 3 | 2024 | 218 | 1.020 |
Why?
| | Skull Base Neoplasms | 4 | 2024 | 30 | 1.000 |
Why?
| | Vagina | 4 | 2021 | 203 | 0.960 |
Why?
| | Cranial Sinuses | 1 | 2024 | 16 | 0.840 |
Why?
| | Neuroma, Acoustic | 2 | 2022 | 55 | 0.810 |
Why?
| | Ovary | 4 | 2020 | 233 | 0.780 |
Why?
| | Intracranial Arteriovenous Malformations | 1 | 2023 | 53 | 0.750 |
Why?
| | Ovarian Neoplasms | 3 | 2020 | 595 | 0.680 |
Why?
| | Contraceptive Devices, Female | 1 | 2021 | 14 | 0.670 |
Why?
| | Pregnenediones | 1 | 2021 | 15 | 0.670 |
Why?
| | Hydrocarbons, Fluorinated | 1 | 2020 | 8 | 0.640 |
Why?
| | Microvascular Decompression Surgery | 1 | 2020 | 4 | 0.640 |
Why?
| | Trigeminal Nerve | 1 | 2020 | 27 | 0.630 |
Why?
| | Uterine Neoplasms | 2 | 2018 | 98 | 0.630 |
Why?
| | Hormone Antagonists | 1 | 2020 | 33 | 0.630 |
Why?
| | Trigeminal Neuralgia | 1 | 2020 | 15 | 0.630 |
Why?
| | Menopause, Premature | 1 | 2020 | 12 | 0.620 |
Why?
| | Salpingo-oophorectomy | 1 | 2020 | 19 | 0.620 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2018 | 193 | 0.590 |
Why?
| | Bacteriophages | 1 | 2021 | 110 | 0.580 |
Why?
| | Neurosurgical Procedures | 5 | 2024 | 202 | 0.570 |
Why?
| | Brain Neoplasms | 3 | 2025 | 1329 | 0.570 |
Why?
| | Frailty | 1 | 2022 | 205 | 0.560 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2020 | 217 | 0.560 |
Why?
| | Uterine Hemorrhage | 1 | 2018 | 41 | 0.550 |
Why?
| | Androgen Antagonists | 1 | 2019 | 91 | 0.550 |
Why?
| | Vaginal Diseases | 1 | 2017 | 19 | 0.530 |
Why?
| | Hypothyroidism | 1 | 2018 | 67 | 0.530 |
Why?
| | Thyrotropin | 1 | 2018 | 120 | 0.520 |
Why?
| | Osteoporosis | 1 | 2020 | 238 | 0.520 |
Why?
| | Hysterectomy | 2 | 2018 | 138 | 0.520 |
Why?
| | Breast Neoplasms | 2 | 2020 | 2382 | 0.520 |
Why?
| | Glioblastoma | 1 | 2021 | 353 | 0.510 |
Why?
| | Cardiovascular System | 1 | 2018 | 138 | 0.490 |
Why?
| | Pyrimidines | 1 | 2020 | 530 | 0.480 |
Why?
| | Testosterone | 2 | 2019 | 416 | 0.460 |
Why?
| | Endoscopy | 3 | 2019 | 317 | 0.460 |
Why?
| | Transgender Persons | 1 | 2019 | 210 | 0.450 |
Why?
| | Humans | 53 | 2026 | 145474 | 0.450 |
Why?
| | Skull Base | 3 | 2022 | 55 | 0.450 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2018 | 187 | 0.440 |
Why?
| | Female | 37 | 2026 | 78844 | 0.420 |
Why?
| | Double-Blind Method | 6 | 2021 | 2062 | 0.390 |
Why?
| | Pneumocephalus | 1 | 2013 | 5 | 0.390 |
Why?
| | Lipids | 1 | 2018 | 707 | 0.380 |
Why?
| | Treatment Outcome | 9 | 2024 | 11772 | 0.360 |
Why?
| | Postoperative Complications | 4 | 2024 | 2970 | 0.360 |
Why?
| | Reproductive Medicine | 1 | 2012 | 18 | 0.350 |
Why?
| | Estrogens, Conjugated (USP) | 1 | 2012 | 52 | 0.350 |
Why?
| | Menopause | 4 | 2020 | 326 | 0.340 |
Why?
| | Endocrinology | 1 | 2012 | 77 | 0.330 |
Why?
| | Hot Flashes | 1 | 2012 | 91 | 0.330 |
Why?
| | Atrophy | 4 | 2021 | 199 | 0.320 |
Why?
| | Intraoperative Complications | 2 | 2023 | 157 | 0.300 |
Why?
| | Sleep Deprivation | 1 | 2012 | 206 | 0.300 |
Why?
| | Meningioma | 2 | 2021 | 88 | 0.270 |
Why?
| | Meningeal Neoplasms | 2 | 2021 | 95 | 0.270 |
Why?
| | Middle Aged | 16 | 2026 | 36215 | 0.270 |
Why?
| | Blood Glucose | 1 | 2018 | 2341 | 0.260 |
Why?
| | Ovarian Hyperstimulation Syndrome | 1 | 2007 | 6 | 0.250 |
Why?
| | Gonadotropins, Pituitary | 1 | 2007 | 22 | 0.250 |
Why?
| | Adult | 18 | 2026 | 40777 | 0.250 |
Why?
| | Insulin | 1 | 2018 | 2512 | 0.250 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2018 | 531 | 0.240 |
Why?
| | Cultural Evolution | 1 | 2025 | 5 | 0.230 |
Why?
| | Moyamoya Disease | 1 | 2025 | 20 | 0.230 |
Why?
| | Aspartic Acid Endopeptidases | 1 | 2025 | 32 | 0.230 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2026 | 71 | 0.230 |
Why?
| | Follicle Stimulating Hormone | 1 | 2007 | 266 | 0.220 |
Why?
| | Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2025 | 35 | 0.220 |
Why?
| | Administration, Intravaginal | 4 | 2021 | 19 | 0.220 |
Why?
| | Gynatresia | 2 | 2020 | 2 | 0.220 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2025 | 78 | 0.220 |
Why?
| | Neuroendoscopy | 1 | 2024 | 24 | 0.210 |
Why?
| | Jugular Veins | 1 | 2024 | 42 | 0.210 |
Why?
| | Microsurgery | 1 | 2024 | 76 | 0.200 |
Why?
| | CRISPR-Cas Systems | 1 | 2025 | 166 | 0.200 |
Why?
| | Urinary Tract Infections | 1 | 2026 | 210 | 0.200 |
Why?
| | Drainage | 2 | 2015 | 185 | 0.190 |
Why?
| | Craniotomy | 1 | 2023 | 84 | 0.190 |
Why?
| | Denervation | 1 | 2022 | 27 | 0.180 |
Why?
| | Pheochromocytoma | 1 | 2023 | 67 | 0.180 |
Why?
| | Insulin Resistance | 2 | 2023 | 1244 | 0.180 |
Why?
| | Paraganglioma | 1 | 2023 | 64 | 0.180 |
Why?
| | Progesterone | 2 | 2021 | 215 | 0.180 |
Why?
| | Health Status Disparities | 1 | 2025 | 321 | 0.180 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2023 | 98 | 0.180 |
Why?
| | Cell Line, Tumor | 4 | 2025 | 3542 | 0.170 |
Why?
| | Wakefulness | 1 | 2023 | 170 | 0.170 |
Why?
| | Cerebral Veins | 1 | 2021 | 16 | 0.170 |
Why?
| | Ethinyl Estradiol | 1 | 2021 | 16 | 0.170 |
Why?
| | Endometrium | 2 | 2015 | 64 | 0.170 |
Why?
| | Risk Factors | 5 | 2022 | 10885 | 0.170 |
Why?
| | Aged | 9 | 2026 | 26153 | 0.160 |
Why?
| | Phytoestrogens | 1 | 2020 | 17 | 0.160 |
Why?
| | Tumor Microenvironment | 1 | 2025 | 734 | 0.160 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2020 | 34 | 0.160 |
Why?
| | Contraceptive Agents | 1 | 2021 | 66 | 0.160 |
Why?
| | Hysteroscopy | 1 | 2020 | 14 | 0.160 |
Why?
| | Pregnancy | 6 | 2021 | 7202 | 0.160 |
Why?
| | Genes, BRCA2 | 1 | 2020 | 33 | 0.160 |
Why?
| | Genes, BRCA1 | 1 | 2020 | 45 | 0.150 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2023 | 265 | 0.150 |
Why?
| | Pneumonia | 1 | 2026 | 636 | 0.150 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2021 | 167 | 0.150 |
Why?
| | Reproductive Techniques, Assisted | 1 | 2020 | 47 | 0.150 |
Why?
| | Drug Combinations | 1 | 2021 | 396 | 0.150 |
Why?
| | Histones | 1 | 2025 | 666 | 0.150 |
Why?
| | Neuroprotection | 1 | 2019 | 46 | 0.150 |
Why?
| | Neutrophils | 1 | 2025 | 1124 | 0.150 |
Why?
| | History, 21st Century | 1 | 2020 | 222 | 0.150 |
Why?
| | Sepsis | 1 | 2026 | 664 | 0.150 |
Why?
| | Body Mass Index | 2 | 2018 | 2445 | 0.150 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 2019 | 38 | 0.150 |
Why?
| | Hormone Replacement Therapy | 2 | 2020 | 107 | 0.140 |
Why?
| | History, 20th Century | 1 | 2020 | 328 | 0.140 |
Why?
| | Complementary Therapies | 1 | 2020 | 95 | 0.140 |
Why?
| | Amenorrhea | 1 | 2018 | 31 | 0.140 |
Why?
| | Seizures | 1 | 2023 | 483 | 0.140 |
Why?
| | Umbilicus | 1 | 2018 | 18 | 0.140 |
Why?
| | Pruritus Vulvae | 1 | 2018 | 1 | 0.140 |
Why?
| | Receptors, Progesterone | 2 | 2021 | 243 | 0.140 |
Why?
| | Candidiasis, Vulvovaginal | 1 | 2018 | 5 | 0.140 |
Why?
| | Retrospective Studies | 5 | 2025 | 17291 | 0.130 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2021 | 456 | 0.130 |
Why?
| | Cerebrospinal Fluid Leak | 2 | 2017 | 70 | 0.130 |
Why?
| | Ohio | 1 | 2018 | 146 | 0.130 |
Why?
| | Acute Kidney Injury | 1 | 2026 | 875 | 0.130 |
Why?
| | Administration, Topical | 1 | 2018 | 153 | 0.130 |
Why?
| | Administration, Oral | 1 | 2020 | 866 | 0.130 |
Why?
| | Symptom Assessment | 1 | 2018 | 136 | 0.130 |
Why?
| | Sinus Pericranii | 1 | 2016 | 1 | 0.130 |
Why?
| | Superior Sagittal Sinus | 1 | 2016 | 3 | 0.130 |
Why?
| | Transverse Sinuses | 1 | 2016 | 9 | 0.130 |
Why?
| | Neoplastic Stem Cells | 1 | 2021 | 409 | 0.120 |
Why?
| | Glucose Tolerance Test | 1 | 2018 | 360 | 0.120 |
Why?
| | Central Nervous System Neoplasms | 1 | 2019 | 177 | 0.120 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2025 | 1189 | 0.120 |
Why?
| | Machine Learning | 1 | 2022 | 587 | 0.120 |
Why?
| | Cross-Over Studies | 1 | 2018 | 608 | 0.120 |
Why?
| | Male | 9 | 2026 | 72842 | 0.120 |
Why?
| | Laparoscopy | 2 | 2018 | 481 | 0.120 |
Why?
| | Decorin | 1 | 2015 | 7 | 0.120 |
Why?
| | Nuclear Proteins | 1 | 2021 | 740 | 0.120 |
Why?
| | Surgical Flaps | 2 | 2017 | 142 | 0.110 |
Why?
| | Cell Proliferation | 2 | 2021 | 2507 | 0.110 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2017 | 189 | 0.110 |
Why?
| | Hospitalization | 1 | 2026 | 2460 | 0.110 |
Why?
| | Peritoneum | 1 | 2015 | 43 | 0.110 |
Why?
| | Robotic Surgical Procedures | 1 | 2018 | 185 | 0.110 |
Why?
| | Myometrium | 1 | 2015 | 38 | 0.110 |
Why?
| | Decision Making, Computer-Assisted | 1 | 2015 | 18 | 0.110 |
Why?
| | Algorithms | 2 | 2015 | 1845 | 0.110 |
Why?
| | Natural Orifice Endoscopic Surgery | 1 | 2015 | 35 | 0.110 |
Why?
| | Proteoglycans | 1 | 2015 | 112 | 0.110 |
Why?
| | Cross-Sectional Studies | 4 | 2026 | 5904 | 0.110 |
Why?
| | Diagnosis, Differential | 2 | 2011 | 1508 | 0.110 |
Why?
| | Endometriosis | 1 | 2015 | 58 | 0.110 |
Why?
| | Product Labeling | 1 | 2014 | 11 | 0.110 |
Why?
| | Biomarkers | 2 | 2018 | 4295 | 0.100 |
Why?
| | Follow-Up Studies | 1 | 2023 | 5423 | 0.100 |
Why?
| | Age Factors | 2 | 2018 | 3342 | 0.100 |
Why?
| | Optic Chiasm | 1 | 2013 | 19 | 0.100 |
Why?
| | Young Adult | 4 | 2025 | 14218 | 0.100 |
Why?
| | Cerebral Ventricles | 1 | 2013 | 56 | 0.090 |
Why?
| | Infertility, Female | 2 | 2020 | 122 | 0.090 |
Why?
| | Triptorelin Pamoate | 1 | 2012 | 19 | 0.090 |
Why?
| | Fertility Agents, Female | 1 | 2012 | 23 | 0.090 |
Why?
| | Risk Assessment | 1 | 2022 | 3747 | 0.090 |
Why?
| | Melanoma | 1 | 2019 | 759 | 0.090 |
Why?
| | Mobile Applications | 1 | 2015 | 199 | 0.090 |
Why?
| | Chorionic Gonadotropin | 1 | 2012 | 78 | 0.090 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2012 | 40 | 0.090 |
Why?
| | Pregnancy, Ectopic | 1 | 2012 | 54 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2025 | 2664 | 0.090 |
Why?
| | Vasomotor System | 1 | 2012 | 46 | 0.090 |
Why?
| | Cognition | 1 | 2019 | 1266 | 0.080 |
Why?
| | Spermatocidal Agents | 1 | 2010 | 6 | 0.080 |
Why?
| | Nonoxynol | 1 | 2010 | 4 | 0.080 |
Why?
| | Betaine | 1 | 2010 | 67 | 0.080 |
Why?
| | Weight Reduction Programs | 1 | 2012 | 140 | 0.080 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2010 | 96 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2930 | 0.080 |
Why?
| | Nose | 2 | 2022 | 67 | 0.070 |
Why?
| | Reference Values | 2 | 2020 | 798 | 0.070 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 6066 | 0.070 |
Why?
| | Ovulation | 1 | 2008 | 46 | 0.070 |
Why?
| | Luteal Phase | 1 | 2008 | 51 | 0.070 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2013 | 641 | 0.070 |
Why?
| | Cohort Studies | 1 | 2018 | 6013 | 0.060 |
Why?
| | United States | 5 | 2026 | 16098 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 2 | 2018 | 2769 | 0.060 |
Why?
| | Quality of Life | 1 | 2018 | 3204 | 0.060 |
Why?
| | Social Learning | 1 | 2025 | 5 | 0.060 |
Why?
| | Fertility | 1 | 2007 | 173 | 0.060 |
Why?
| | Obesity | 2 | 2023 | 3116 | 0.050 |
Why?
| | Ovulation Induction | 1 | 2004 | 65 | 0.050 |
Why?
| | Vasodilator Agents | 1 | 2006 | 330 | 0.050 |
Why?
| | Embryo Transfer | 1 | 2004 | 45 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 3 | 2017 | 3904 | 0.050 |
Why?
| | Infertility | 1 | 2004 | 61 | 0.050 |
Why?
| | Mental Disorders | 1 | 2013 | 1163 | 0.050 |
Why?
| | Piperazines | 1 | 2006 | 375 | 0.050 |
Why?
| | Carcinoembryonic Antigen | 1 | 2023 | 40 | 0.050 |
Why?
| | Succinate Dehydrogenase | 1 | 2023 | 65 | 0.050 |
Why?
| | Mice | 3 | 2025 | 18329 | 0.050 |
Why?
| | Ultrasonography | 1 | 2007 | 785 | 0.050 |
Why?
| | Otolaryngologists | 1 | 2022 | 13 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2023 | 176 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2025 | 934 | 0.040 |
Why?
| | Cell Adhesion Molecules | 1 | 2023 | 181 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2025 | 635 | 0.040 |
Why?
| | Parietal Lobe | 1 | 2021 | 61 | 0.040 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2004 | 268 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2023 | 287 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2012 | 2214 | 0.040 |
Why?
| | Illinois | 1 | 2020 | 49 | 0.040 |
Why?
| | Chicago | 1 | 2020 | 62 | 0.040 |
Why?
| | Tissue Adhesions | 1 | 2020 | 34 | 0.040 |
Why?
| | Hormones | 1 | 2020 | 135 | 0.040 |
Why?
| | Antigens, CD | 1 | 2023 | 558 | 0.040 |
Why?
| | Fertility Preservation | 1 | 2020 | 55 | 0.040 |
Why?
| | NF-kappa B | 1 | 2023 | 666 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2025 | 1443 | 0.040 |
Why?
| | Treatment Failure | 1 | 2020 | 360 | 0.040 |
Why?
| | Prevalence | 1 | 2026 | 2865 | 0.040 |
Why?
| | Incidence | 1 | 2025 | 2923 | 0.030 |
Why?
| | Choice Behavior | 1 | 2020 | 180 | 0.030 |
Why?
| | Retroperitoneal Space | 1 | 2018 | 18 | 0.030 |
Why?
| | Abdominal Wall | 1 | 2018 | 28 | 0.030 |
Why?
| | Parity | 1 | 2018 | 111 | 0.030 |
Why?
| | Animals | 3 | 2025 | 38030 | 0.030 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2018 | 67 | 0.030 |
Why?
| | Tumor Burden | 1 | 2018 | 325 | 0.030 |
Why?
| | Aging | 1 | 2008 | 1969 | 0.030 |
Why?
| | Angiography, Digital Subtraction | 1 | 2016 | 48 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2023 | 874 | 0.030 |
Why?
| | Recurrence | 1 | 2020 | 1138 | 0.030 |
Why?
| | Drug Therapy | 1 | 2017 | 84 | 0.030 |
Why?
| | Artificial Intelligence | 1 | 2021 | 381 | 0.030 |
Why?
| | Promegestone | 1 | 2015 | 9 | 0.030 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2017 | 117 | 0.030 |
Why?
| | Radiotherapy | 1 | 2017 | 204 | 0.030 |
Why?
| | Insurance, Health | 1 | 2018 | 310 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 439 | 0.030 |
Why?
| | Cell Line, Transformed | 1 | 2015 | 138 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2023 | 1581 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 208 | 0.030 |
Why?
| | Disease Management | 1 | 2019 | 653 | 0.030 |
Why?
| | Income | 1 | 2015 | 202 | 0.030 |
Why?
| | Liver | 1 | 2023 | 1896 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2018 | 8333 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2018 | 1323 | 0.030 |
Why?
| | Immunotherapy | 1 | 2019 | 666 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2015 | 397 | 0.020 |
Why?
| | Educational Status | 1 | 2015 | 466 | 0.020 |
Why?
| | Endometrial Neoplasms | 1 | 2015 | 205 | 0.020 |
Why?
| | Blotting, Western | 1 | 2015 | 1179 | 0.020 |
Why?
| | Databases, Factual | 1 | 2018 | 1490 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2023 | 5983 | 0.020 |
Why?
| | Biopsy | 1 | 2015 | 1082 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2015 | 1716 | 0.020 |
Why?
| | Gels | 1 | 2010 | 85 | 0.020 |
Why?
| | Societies, Medical | 1 | 2015 | 899 | 0.020 |
Why?
| | Adolescent | 2 | 2025 | 22529 | 0.020 |
Why?
| | Child, Preschool | 1 | 2025 | 11853 | 0.020 |
Why?
| | Pregnanediol | 1 | 2008 | 23 | 0.020 |
Why?
| | Estrone | 1 | 2008 | 41 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2015 | 3623 | 0.020 |
Why?
| | Decision Making | 1 | 2015 | 977 | 0.020 |
Why?
| | Sildenafil Citrate | 1 | 2006 | 60 | 0.010 |
Why?
| | Sulfones | 1 | 2006 | 127 | 0.010 |
Why?
| | Purines | 1 | 2006 | 187 | 0.010 |
Why?
| | Women's Health | 1 | 2006 | 314 | 0.010 |
Why?
| | Prospective Studies | 1 | 2015 | 8057 | 0.010 |
Why?
|
|
Liu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|